Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- FRPT +12.1%, LI +8.9%, DPZ +7.7%, BCRX +6.3%, PPC +5.6%, BRK.B +2.2%, KOS +1.5%
Other news:
- ALVO +11.4% (Alvotech and Teva (TEVA) announce U.S. approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira; accepts offer for the sale of shares for a value of ~$166 million at a purchase price of $16.41 (ISK 2,250) per share)
- TEVA +5.1% (Alvotech and Teva (TEVA) announce U.S. approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira)
- CLDX +3.5% (Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria)
- KALV +3.3% (Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting)
- LZM +1.1% (announces two-phased development plan for the kabanga nickel project in Tanzania)
- NVDA +1% (Positive Barrons article)
- AVGO +0.9% (KKR (KKR) nearing deal to purchase software unit from Broadcom)
Analyst comments:
- FLNC +5.6% (upgraded to Positive from Neutral at Susquehanna)
- CE +1.8% (upgraded to Overweight from Neutral at Piper Sandler)